Last reviewed · How we verify
NCT03870464
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
trial testing CT-scans extended in Non-small Cell Lung Cancer in 150 participants. Participants enrolled and being followed up; not accepting new ones.
8 November 2022
Quick facts
| Lead sponsor | University of Southern Denmark |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 April 2018 |
| Primary completion | 8 November 2022 |
| Estimated completion | 1 April 2028 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- CT-scans extended
- MRI scan of the brain
- Prospective registration of irAEs
- Quality of Life questionnaires
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Quality of Life — all drugs for Quality of Life →
- Brain Metastases — all drugs for Brain Metastases →
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
Sponsor
University of Southern Denmark
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.
Bjørnhart B, Hansen KH, Asmussen JT, Jørgensen TL, et al · · 2022 · cited 4× · PMID 35406453 · DOI 10.3390/cancers14071682
Verify or expand the search:
- PubMed search for NCT03870464
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other University of Southern Denmark trials
Trials by the same sponsor.
- NCT07531290 — PeerScreen Trial - Reducing Screen Media Use in Peer-groups of Young People · NA · not yet recruiting
- NCT07384273 — Evaluating the Effectiveness of an Internet-based Therapy (iCARE) to Treat Symptoms of Postpartum Depression · NA · recruiting
- NCT07426679 — Should Anaesthesiologists Be Taught to Perform Ultrasound-- Assisted Neuraxial Access in Spinal Anaesthesia? · NA · recruiting
- NCT07104292 — Pelvic Floor Muscle Training During Pregnancy · NA · recruiting
- NCT07194759 — Health Literacy Levels of Patients Living With Type 2 Diabetes and Multi-disease and Their Families Using HLQTM · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03870464 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern Denmark
- Last refreshed: 7 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03870464.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing